Oncotarget

Research Papers:

18F-fluorodeoxyglucose positron emission tomography-computed tomography as a screening tool for second primary cancers in cancer patients

Yang Liu, Jie Ma and Yingxin Liu _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:92555-92560. https://doi.org/10.18632/oncotarget.21444

Metrics: PDF 1227 views  |   HTML 1680 views  |   ?  


Abstract

Yang Liu1,*, Jie Ma2,* and Yingxin Liu1

1Department of Radiation Oncology, Cancer Hospital of Guangxi Medical University, Nanning, People’s Republic of China

2Department of Radiology, Cancer Hospital of Guangxi Medical University, Nanning, People’s Republic of China

*The co-first authors

Correspondence to:

Yingxin Liu, email: [email protected]

Keywords: second primary cancers, PET-CT, staging

Received: August 03, 2017     Accepted: August 18, 2017     Published: September 30, 2017

ABSTRACT

Background: We performed a meta-analysis to evaluate the value of 18F-fluorodeoxyglucose positron emission tomography-computed tomography (18FDG PET-CT) for the detection of second primary cancers in cancer patients.

Results: This present study analyzed a total of 6 selected studies (1374 patients). The sensitivity and specificity of PET-CT were 0.84 (95% confidence interval [CI] = 0.66 to 0.93), and 0.98 (95% CI = 0.97 to 0.98). Area under the curve was 0.98 (95% CI = 0.96 to 0.99).

Methods: Studies were systematically searched for relevant PET-CT original articles in the MEDLINE and EMBASE databases. We calculated the pooled sensitivity, specificity, and likelihood ratios for 18FDG PET-CT. We also constructed the summary receiver-operating characteristic curve for 18FDG PET-CT.

Conclusions: 18FDG PET-CT has high sensitivity and specificity for the detection of second primary cancers in cancer patients.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 21444